Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Heart Failure With LVEF ≥40%
CTR20201880Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of finerenone in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF), sponsored by Bayer. Started Sep 2020; status: completed.
02
Drugs
finerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on CTR20201880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201880.